Areca nut chewing and the risk of re-hospitalization and mortality among patients with acute coronary syndrome in Pakistan by Karim, Muhammad Tariq et al.
Journal of 
Preventive Medicine 
& Public Health
71Copyright © 2018  The Korean Society for Preventive Medicine
Journal of 
Preventive Medicine 
& Public Health
PB Copyright © 2018  The Korean Society for Preventive Medicine
J Prev Med Public Health 2018;51:71-82    •  https://doi.org/10.3961/jpmph.17.189
Areca Nut Chewing and the Risk of Re-hospitalization 
and Mortality Among Patients With Acute Coronary  
Syndrome in Pakistan
Muhammad Tariq Karim1, Sumera Inam2, Tariq Ashraf3, Nadia Shah2, Syed Omair Adil4, Kashif Shafique2,5
1Research Evaluation Unit, College of Physicians and Surgeons Pakistan, Karachi, Pakistan; 2School of Public Health, Dow University of Health  
Sciences, Karachi, Pakistan; 3National Institute of Cardiovascular Diseases, Karachi, Pakistan; 4Department of Research, Dow University of Health 
Sciences, Karachi, Pakistan; 5Institute of Health and Wellbeing, Public Health, University of Glasgow, Glasgow, UK
Original Article
Objectives: Areca nut is widely consumed in many parts of the world, especially in South and Southeast Asia, where cardiovascular 
disease (CVD) is also a huge burden. Among the forms of CVD, acute coronary syndrome (ACS) is a major cause of mortality and mor-
bidity. Research has shown areca nut chewing to be associated with diabetes, hypertension, oropharyngeal and esophageal cancers, 
and CVD, but little is known about mortality and re-hospitalization secondary to ACS among areca nut users and non-users.
Methods: A prospective cohort was studied to quantify the effect of areca nut chewing on patients with newly diagnosed ACS by cat-
egorizing the study population into exposed and non-exposed groups according to baseline chewing status. Cox proportional haz-
ards models were used to examine the associations of areca nut chewing with the risk of re-hospitalization and 30-day mortality sec-
ondary to ACS. 
Results: Of the 384 ACS patients, 49.5% (n=190) were areca users. During 1-month of follow-up, 20.3% (n=78) deaths and 25.1% 
(n=96) re-hospitalizations occurred. A higher risk of re-hospitalization was found (adjusted hazard ratio [aHR], 2.05; 95% confidence 
interval [CI], 1.29 to 3.27; p=0.002) in areca users than in non-users. Moreover, patients with severe disease were at a significantly 
higher risk of 30-day mortality (aHR, 2.77; 95% CI, 1.67 to 4.59; p<0.001) and re-hospitalization (aHR, 2.72; 95% CI, 1.73 to 4.26; 
p<0.001). 
Conclusions: The 30-day re-hospitalization rate among ACS patients was found to be significantly higher in areca users and individu-
als with severe disease. These findings suggest that screening for a history of areca nut chewing may help to identify patients at a 
high risk for re-hospitalization due to secondary events. 
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INTRODUCTION 
Approximately 600 million individuals throughout the world 
chew areca nut, making it the fourth leading form of sub-
stance abuse worldwide, and more than a quarter of areca nut 
users live in South Asia [1,2]. Areca nut chewing is emerging as 
a public health challenge in many Western countries due to 
the immigration of youth from Asia and Africa to these coun-
Muhammad Tariq Karim, et al.
72
tries. Areca nuts are the main component of the vast majority 
of commonly consumed chewing products, including betel 
quid (paan), gutka, and supari. Areca nut is consumed in sev-
eral forms, including green/unripe, ripe, raw, boiled/roasted, 
or fermented, in high-consuming countries such as India 
(where 46.4% of males and 20% of females consume gutka), 
Pakistan (with areca nut consumption rates of 50.3% for males 
and 28.5% for females) [3], Nepal, Bangladesh, Sri Lanka, Thai-
land, Malaysia, Indonesia, China, Cambodia, and Papua New 
Guinea. Additional sweeteners and flavors such as cloves, am-
ber, coconut, mace, sugar crystals, nutmeg, camphor; tobacco, 
and lime are added as flavor enhancers [2].
Several studies have shown that areca nut chewing is linked 
with cancer of the oral cavity, esophagus, and liver, as well as 
cirrhosis of the liver [4-10]. Furthermore, some evidence also 
suggests that areca nut chewing is linked with obesity, type 2 
diabetes mellitus (DM), hypertension (HTN), dyslipidemia, 
metabolic syndrome, and chronic kidney disease [11-15], 
which are also well-known risk factors of cardiovascular dis-
ease (CVD) [16,17]. CVD is still the leading cause of mortality 
globally, and the South Asian population is expected to signifi-
cantly contribute to global CVD morbidity and mortality in de-
cades to come. 
Evidence from prospective studies suggests that areca nut 
chewing significantly amplifies the risk of all-cause and cardio-
vascular mortality [18,19]. Betel quid causes instant effects of 
vasoconstriction, an elevated pulse rate, and raised blood 
pressure [20]. Since it contains arsenic and manganese, it may 
increase the risk of HTN in chewers. Further, it also stimulates 
the sympathetic nervous system, resulting in the secretion of 
adrenal medullary catecholamine, which is linked to elevated 
homocysteine levels, another risk factor for heart disease. 
Moreover, periodontal disease, a known risk factor for CVD, is 
also a consequence of consuming betel quid [21]. A pooled 
analysis of 12 studies reported increased risk of developing 
CVD’s (relative risk [RR], 1.20, p<0.05) and of all-cause mortali-
ty (RR, 1.21, p<0.05) among areca nut chewers compared 
with non-chewers [22]. 
Among the forms of CVD, acute coronary syndrome (ACS) 
accounts for approximately 3.5 million hospital admissions 
worldwide [23]. Considerable disparities exist in the incidence 
and mortality of ACS from country to country. These dispari-
ties are also partly explained by differences in lifestyle habits 
and the prevalence of various cardiovascular risk factors [24]. 
Some evidence suggests that long-term areca nut chewing 
increases the risk of ACS by 3-fold (odds ratio [OR], 3.5; 95% 
confidence interval [CI], 2.0 to 6.2) [25]. However, there is little 
published evidence regarding the relationship of long-term 
areca nut chewing with the prognosis of patients who develop 
ACS. Given that 15 to 30% of patients with ACS either are re-
hospitalized or die within 30 days of the acute event, it is im-
portant to understand the effects of areca nut chewing on the 
prognosis of these patients. Therefore, the purpose of the 
study was to determine the short-term (30-day) risk of re-hos-
pitalization and mortality among ACS patients according to 
baseline areca nut chewing. 
METHODS
Study Setting
This study was a hospital-based prospective cohort study 
conducted in 2014-2015. The study was conducted at the De-
partment of Cardiology, Civil Hospital Karachi and the National 
Institute of Cardiovascular Diseases. Both of these are tertiary 
care hospitals, serving more than 60% of CVD patients in Kara-
chi, the largest city of Pakistan, at low cost.  
Cohort Selection
ACS represents “a set of clinical sign and symptoms similar 
to acute myocardial ischemia, covering clinical conditions 
from unstable angina to none-ST-segment elevation myocar-
dial infarction (NSTEMI) to ST-segment elevation myocardial 
infarction (STEMI)” [26].
Patients were diagnosed with ACS by a consultant cardiologist 
at the time of presentation with any of the following conditions:  
 STEMI: “A history of typical chest pain for more than 20 min-
utes with ST elevation at the J point of ≥2 mm (0.2 mV) in 
at least 2 contiguous leads in males ≥1.5 mm (0.15 mV) in 
females in leads V2-V3, or ≥1 mm (0.1 mV) in other contig-
uous chest or the limb leads.”
 NSTEMI: “A history of typical chest pain for >20 minutes 
with electrocardiogram (ECG) changes such as ST depres-
sion and raised creatine kinase-MB (CKMB) enzymes and 
troponin levels.”
 Unstable angina: The presence of 1 or more of the following 
presentations without elevated CKMB enzymes or troponin 
was labeled as rest angina (usually lasting >20 minutes), 
new-onset angina (<2 months previously), or an increased 
pattern of occurrence (increasing in duration, intensity, and/
or frequency).
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Only newly admitted patients 30-70 years of age with a di-
agnosis of ACS at the time of admission were included in the 
study. Subjects with congenital heart disease, any previous or 
family history of ACS, or valvular or rheumatic heart disease 
were excluded from this study.  
Data Collection Tool
A standardized questionnaire was used by a team of well-
trained researchers to interview patients, gathering informa-
tion about their demographic characteristics, lifestyle, health 
behaviors, and history of chewing areca nut. All information 
was collected by face-to-face interviews with patients within 
the first 48 hours of hospital admission. 
The socio-demographic measures included age (30-40, 40-
50, 50-60, and >60 years), sex (male or female), monthly in-
come (used to define socioeconomic status [SES] as below av-
erage or average) and employment status (employed or un-
employed). Health behaviors, particularly physical activity, 
were captured through self-reporting, and patients who re-
ported no activity or less than 150 minutes of activity per 
week were labeled as physically inactive. Patients were also 
asked about their smoking status, and based on their respons-
es were classified as “never smokers (those who had never 
smoked a cigarette), current smokers (those who reported 
smoking at least 100 cigarettes during their lifetime and re-
ported smoking every day or some days at the time of partici-
pation), and ex-smokers (individuals who had quit smoking 
for at least 6 months)”. Physical measures included measure-
ments of weight, height, blood pressure, and body mass index 
(BMI, kg/m2). BMI was categorized according to the standard 
World Health Organization BMI cut-offs that classify “normal 
weight as <23.0 kg/m2, overweight as 23.0-26.9 kg/m2, and 
obese as ≥27.0 kg/m2” [27]. Patients were classified as having 
DM if they had “a self-reported history of DM, were on anti-di-
abetic medications, or had abnormal fasting blood glucose 
levels (blood glucose concentration ≥110 mg/dL)”. HTN was 
defined as “a blood pressure ≥140 (systolic)/90 (diastolic) 
mmHg, previously diagnosed HTN, the usage of anti-hyper-
tensive medications”. 
According to the guidelines of the American Heart Associa-
tion, the current pathway for assessing patients who may have 
ACS is based on the following 4 main diagnostic tools: “clinical 
history, ECG results, levels of cardiac markers, and the results 
of stress testing. On the basis of this initial information, pa-
tients are assigned to one of 4 categories: a non-cardiac diag-
nosis, chronic stable angina, possible ACS, or definite ACS”. 
Based on the diagnosis made by the cardiologist, we generat-
ed a variable for the initial severity of disease. Respondents 
with ‘unstable/mild angina’ were classified as having ‘non-se-
vere disease’, whereas ‘possible myocardial infarction/definite’ 
ACS were considered to indicate ‘severe initial disease’.
Exposure Definition
Patients who persistently consumed areca nut on daily basis 
(on average 2-3 times a day) for more than 5 years were consid-
ered to be exposed [28,29], and were coded as ‘yes’ for this vari-
able, while those who never used or had quit consuming areca 
for more than a year were considered to be non-exposed and 
coded as ‘no’ for this variable. Patients categorized as exposed 
were asked about the form of areca nut they used. Respon-
dents who consumed “unripe or ripe; whole or sliced; raw, 
roasted, or sun-dried; boiled or soaked in water; or fermented 
(under mud) areca nut” were considered to consume areca nut 
‘without additives’. In contrast, “mixtures of areca nut and fla-
voring ingredients with processed tobacco leaves, slaked lime, 
catechus, sweeteners, spices, piper betel, and essences” were 
considered to be forms ‘with additives or tobacco’  [30].
Follow-up 
The follow-up of ACS patients started once they were dis-
charged from the hospital. Patients were followed regularly in 
the outpatient clinic, and the final outcomes were recorded 
after 30 days had passed from the time of discharge. The out-
comes: 30-day mortality and 30-day re-hospitalization were 
measured separately. Mortality was defined as death within 
30 days due to any cardiac problem from the index admission 
date, and re-hospitalization was defined as readmission to the 
hospital due to any cardiac problem within 30 days from the 
discharge date. Therefore, 2 survival times were defined: the 
time from entry to death from CVD (within 30 days) and the 
time from entry to re-hospitalization (within 30 days) due to 
any cardiac problems. 
For patients who did not return in 30 days, a telephone call 
was made by the researchers to evaluate their vital status and 
any cardiac re-hospitalization event in the 30 days after dis-
charge. Only the first re-hospitalization within 30 days of dis-
charge was considered a 30-day readmission. However, if a re-
admitted patient died within this 30-day period, then in the 
re-hospitalization multivariate model, that patient’s follow-up 
was truncated at the date of re-hospitalization.
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Sample Size Estimation
The sample size was calculated using the expected propor-
tions of mortality in the exposed (30%) [31] and unexposed 
(15%) groups with a 95% confidence level and 80% power of 
the test. Accordingly, the minimum sample size for this study 
was 268, which was upsized to reduce estimation bias from 
loss to follow-up. The final estimated sample size was 384.  
Ethical Approval
The study protocol was approved by the institutional review 
board (IRB) of Dow University of Health Sciences, Karachi, Paki-
stan (IRB no. IRB-514/DUHS/-14). Informed consent was ob-
tained from all study participants prior to conducting the 
study. 
Statistical Analysis
For data analysis, Stata version 11 (StataCorp., College Sta-
tion, TX, USA) was used. Demographic characteristics, history 
of substance use, and the prevalence of comorbidities in pa-
tients with ACS were recorded. The statistical analysis included 
the chi-square test, as well as Cox proportional hazards regres-
sion with a significance level of 0.05 to examine the associa-
tions of areca use and other explanatory variables with 30-day 
mortality and re-hospitalization, which were the dependent 
variables used in the current study. Univariate analyses were 
performed using a Cox proportional hazards regression model 
to estimate the magnitude of the effect of areca nut chewing 
on 30-day mortality and re-hospitalization of ACS patients. 
Multivariable proportional hazards regression models were 
further applied, and the adjusted hazard ratio (aHR) for areca 
nut chewing was computed after adjusting for the confound-
ers identified in the univariate analyses (p=0.25) separately 
for both 30-day mortality and re-hospitalization, including the 
following covariates: age, sex, BMI, smoking status, initial se-
verity of disease, SES, exercise status, employment status, DM, 
and HTN. 
RESULTS
A total of 384 patients with ACS were included in this study, 
among whom 38.2% (n=147) were diagnosed with severe 
disease. During 1-month follow-up, death occurred in 20.3% 
(n=78) of the patients and re-hospitalization in 25.0% (n=96). 
Of the patients, 49.5% (n=190) were areca nut users, among 
whom 78.9% (n=150) were users of areca nut with additives. 
A significant association was observed between areca use and 
30-day re-hospitalization (p<0.001). 
Further, significant associations were found between dis-
ease severity and 30-day mortality (p<0.001) and re-hospital-
ization (p<0.001). Among the patients with severe initial dis-
ease, 39.5% (n=58) were re-hospitalized and 34.0% (n=50) 
died within the 1-month follow-up. 
Of the ACS patients, 72.1% (n=277) were male and 27.9% 
(n=107) were female. Males were more likely to use areca nut 
with tobacco additives than females (p=0.008). Death within 
30 days occurred in 22.0% (n=61) of the male patients and 
15.9% (n=17) of the female patients, and re-hospitalization 
took place in 25.6% (n=71) of the male patients and 23.4% 
(n=25) of the female patients. However, no statistically signifi-
cant association was found between sex and 30-day mortality 
(p=0.18) or 30-day re-hospitalization (p=0.65). 
Of the 286 smokers, 29.6% (n=114) were current smokers 
and 18.8% (n=72) were ex-smokers. The 30-day mortality rate 
was 32.5% (n=37) and 13.9% (n=10) in current smokers and 
ex-smokers, respectively, and the 30-day re-hospitalization 
rate was 35.1% (n=40) and 19.4% (n=14) in current smokers 
and ex-smokers, respectively. Respondents with a normal BMI 
(n=80), overweight (n=200), and obesity (n=104) had 30-
day mortality rates of 23.7% (n=19), 24.0% (n=48), and 10.6% 
(n=11), respectively, and 30-day re-hospitalization rates of 
28.8% (n=23), 27.0% (n=54), and 18.3% (n=19), respectively. 
The chi-square test showed significant associations of current 
smoking with 30-day mortality (p<0.01) and re-hospitaliza-
tion (p=0.01). Furthermore, BMI was also significantly (p=  
0.01) associated with mortality among the ACS patients. 
Among the patients with DM, 12.9% (n=17) died, whereas 
87.1% (n=115) remained alive over the 30-day follow-up, and 
19.7% (n=26) were re-hospitalized. Similarly, among patients 
with HTN, 16.4% (n=32) and 23.6% (n=46) died and were re-
hospitalized, respectively. A significant association was ob-
served between DM and 30-day mortality (p=0.009). There 
were no significant associations of mortality and re-hospital-
ization with age, SES, employment status, or HTN. Table 1 sum-
marizes the basic characteristics of the study sample.
Univariate Analyses
In the univariate Cox proportional hazards regression analy-
ses, areca nut users had a higher risk of 30-day re-hospitaliza-
tion (hazard ratio [HR], 2.09; 95% CI, 1.37 to 3.18; p<0.001) 
and 30-day mortality (HR, 1.43; 95% CI, 0.91 to 2.24; p=0.11) 
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than non-users. Moreover, patients with severe disease had a 
higher risk of both 30-day re-hospitalization (HR, 2.69; 95% CI, 
1.79 to 4.06; p<0.001) and 30-day mortality (HR, 3.17; 95% CI, 
1.99 to 5.03; p<0.001). Current smokers also had a higher risk 
Table 1. Baseline characteristics by status mortality and re-hospitalization (n=384)
Characteristics Total
Re-hospitalization Mortality
Yes No p-value1 Yes No p-value1
Areca use
   No 194 (50.5) 33 (17.0) 161 (82.9) <0.001 33 (17.0) 161 (82.9) 0.10
   Yes 190 (49.5) 63 (33.2) 127 (66.8) 45 (23.7) 145 (76.3)
Areca type (n=190)
   Without additive 40 (21.1) 14 (35.0) 26 (65.0) 0.78 12 (30.0) 28 (70.0) 0.29
   Additive 150 (78.9) 49 (32.7) 101 (67.3) 33 (22.0) 117 (78.0)
Smoking status
   Never smoked 198 (51.5) 42 (21.2) 156 (78.8) 0.01 31 (15.6) 167 (84.3) <0.001
   Current smokers 114 (29.6) 40 (35.1)  74 (64.9) 37 (32.5) 77 (67.5)
   Ex-smokers 72 (18.8) 14 (19.4)  58 (80.6) 10 (13.9) 62 (86.1)
Disease sverity
   No 237 (61.7) 38 (16.0) 199 (83.9) <0.001 28 (11.8) 209 (88.2) <0.001
   Yes 147 (38.2) 58 (39.5) 89 (60.5) 50 (34.0) 97 (65.9)
Age (y)
   30-40 50 (13.0) 12 (24.0) 38 (76.0) 0.23 9 (18.0) 41 (82.0) 0.26
   40-50 116 (30.2) 31 (26.7) 85 (73.3) 30 (25.9) 86 (74.1)
   50-60 121 (31.5) 23 (19.0) 98 (80.9) 19 (15.7) 102 (84.3)
   >60 97 (25.3) 30 (30.9) 67 (69.1) 20 (20.6) 77 (79.4)
Sex
   Male 277 (72.1) 71 (25.6) 206 (74.4) 0.65 61 (22.0) 216 (77.9) 0.18
   Female 107 (27.9) 25 (23.4) 82 (76.6) 17 (15.9) 90 (84.1)
Body mass index
   Normal 80 (20.8) 23 (28.8) 57 (71.2) 0.17 19 (23.7) 61 (76.3) 0.01
   Over weight 200 (52.1) 54 (27.0) 146 (73.0) 48 (24.0) 152 (76.0)
   Obese 104 (27.1) 19 (18.3) 85 (81.7) 11 (10.6) 93 (89.4)
Socioeconomic status 
   Below average 117 (30.5) 24 (20.5) 93 (79.5) 0.18 17 (14.5) 100 (85.5) 0.06
   Average 267 (69.5) 72 (26.9) 195 (73.0) 61 (22.8) 206 (77.2)
Occupation
   Unemployed 159 (41.4) 33 (20.8) 126 (79.2) 0.11 25 (15.7) 134 (84.3) 0.06
   Employed 225 (58.6) 63 (28.0) 162 (72.0) 53 (23.5) 172 (76.4)
Physically active
   No 343 (89.3) 91 (26.5) 252 (73.5) 0.04 71 (20.7) 272 (79.3) 0.59
   Yes 41 (10.7) 5 (12.2) 36 (87.8) 7 (17.1) 34 (82.9)
Diabetes mellitus 
   No 252 (65.6) 70 (27.8) 182 (72.2) 0.08 61 (24.2) 191 (75.8) 0.009
   Yes 132 (34.4) 26 (19.7) 106 (80.3) 17 (12.9) 115 (87.1)
Hypertension
   No 189 (49.2) 50 (26.5) 139 (73.5) 0.52 46 (24.3) 143 (75.7) 0.05
   Yes 195 (50.8) 46 (23.6) 149 (76.4)  32 (16.4) 163 (83.6)
Values are presented as number (%).
1Chi-square test.
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of both 30-day mortality (HR, 2.23; 95% CI, 1.38 to 3.59; 
p<0.001) and 30-day re-hospitalization (HR, 1.73; 95% CI, 1.12 
to 2.67; p=0.01) than non-smokers. Respondents who were 
obese or had DM had a significantly lower risk of 30-day mor-
tality (Table 2). 
Table 2. Areca nut use and risk of 30-day re-hospitalization and mortality among ACS patients: univariate analysis1
Characteristics
Re-hospitalization Mortality
HR (95% CI) p-value HR (95% CI) p-value
Areca use
   No 1.00 (reference) 1.00 (reference)
   Yes 2.09 (1.37, 3.18) <0.001 1.43 (0.91, 2.24) 0.11
Areca type
   Without additive 1.00 (reference) 1.00 (reference)
   Additive 0.98 (0.54, 1.79) 0.97 0.74 (0.38, 1.44) 0.39
Smoking status
   Never smoked 1.00 (reference) 1.00 (reference)
   Current smokers 1.73 (1.12, 2.67) 0.01 2.23 (1.38, 3.59) <0.001
Disease severity
   No 1.00 (reference) 1.00 (reference)
   Yes 2.69 (1.79, 4.06) <0.001 3.17 (1.99, 5.03) <0.001
Age (y)
   30-40 1.00 (reference) 1.00 (reference)
   40-50 1.16 (0.59, 2.27) 0.65 1.47 (0.70, 3.11) 0.30
   50-60 0.80 (0.40, 1.62) 0.55 0.85 (0.38, 1.86) 0.71
   >  60 1.41 (0.72, 2.75) 0.31 1.17 (0.53, 2.58) 0.69
Sex
   Male 1.00 (reference) 1.00 (reference)
   Female 0.89 (0.56, 1.41) 0.64 0.68 (0.40, 1.18) 0.17
Body mass index
   Normal 1.00 (reference) 1.00 (reference)
   Over weight 0.93 (0.57, 1.52) 0.79 1.04 (0.61, 1.77) 0.87
   Obese 0.59 (0.32, 1.08) 0.09 0.42 (0.20, 0.89) 0.02
Socioeconomic status 
   Average 1.00 (reference) 1.00 (reference)
   Below average 0.75 (0.47, 1.19) 0.234 0.61 (0.36, 1.05) 0.08
Occupation
   Un-employed 1.00 (reference) 1.00 (reference)
   Employed 0.68 (0.45, 1.04) 0.08 0.62 (0.39, 1.01) 0.06
Physically active
   No 1.00 (reference) 1.00 (reference)
   Yes 0.41 (0.16, 1.02) 0.057 0.76 (0.35, 1.65) 0.49
Diabetes mellitus 
   No 1.00 (reference) 1.00 (reference)
   Yes 0.66 (0.42, 1.03) 0.07 0.49 (0.28, 0.84) 0.01
Hypertension
   No 1.00 (reference) 1.00 (reference)
   Yes 0.87 (0.58, 1.30) 0.51 0.64 (0.41, 1.01) 0.06
ACS, acute coronary syndrome; HR, hazard ratios; CI, confidence interval.
1Cut-off ≤0.25: a univariate cut-off value to shortlist variables for multivariable analyses.
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Multivariate Analyses  
Areca nut chewers had a significantly increased risk (aHR, 
2.05; 95% CI, 1.29 to 3.27; p=0.002) of re-hospitalization with-
in 30-days compared with non-chewers after adjusting for dis-
ease severity, SES, employment status, physical activity, smok-
ing status, and DM. Patients diagnosed with severe disease 
had a significantly higher risk of re-hospitalization (aHR, 2.72; 
95% CI, 1.73 to 4.26; p<0.001). Current smokers (aHR, 1.28; 
95% CI, 0.81 to 2.04; p=0.28) had a higher but non-significant-
ly increased risk of re-hospitalization compared with non-
smokers. Respondents who had below-average SES, were un-
employed, were physically active, or had DM showed lower 
but non-significantly reduced risks of 30-day re-hospitaliza-
tion.
Respondents who chewed areca nut had a slightly increased 
risk of 30-day mortality (aHR, 1.65; 95% CI, 0.99 to 2.75; 
p=0.05) compared with non-chewers after adjusting for sex, 
disease severity, SES, employment status, smoking status, DM, 
and HTN. However, we also observed a significant higher risk 
of 30-day mortality (aHR, 2.77; 95% CI, 1.67 to 4.59; p<0.001) 
among patients with severe disease. Females (aHR, 1.15; 95% 
CI, 0.54 to 2.42; p=0.71) were found to be at a higher but non-
significant increased risk for 30-day mortality compared with 
males. Individuals, who had below-average SES, were unem-
ployed, or had DM or HTN had a lower but non-significant re-
duced risk of 30-day mortality (Table 3).
The overall findings of a significant increase in the risk of re-
hospitalization and a non-significant increase in the risk of 
Table 3. Areca nut use and risk of 30-day mortality and re-hospitalization among ACS patients: multivariate analysis
Characteristics
Re-hospitalization1 Mortality2
aHR (95% CI) p-value aHR (95% CI) p-value
Areca use
   No 1.00 (reference) 1.00 (reference)
   Yes 2.05 (1.29, 3.27) 0.002 1.65 (0.99, 2.75) 0.05
Smoking status
   Never smoked 1.00 (reference) 1.00 (reference)
   Current smokers 1.28 (0.81, 2.04) 0.28 1.61 (0.91, 2.84) 0.10
Disease severity 
   No 1.00 (reference) 1.00 (reference)
   Yes 2.72 (1.73, 4.26) <0.001 2.77 (1.67, 4.59) <0.001
Sex
   Male 1.00 (reference)
   Female - - 1.15 (0.54, 2.42) 0.71
SES
   Average 1.00 (reference) 1.00 (reference)
   Below average 0.87 (0.52, 1.46) 0.62 0.75 (0.41, 1.36) 0.35
Employment status
   Unemployed 1.00 (reference) 1.00 (reference)
   Employed 0.76 (0.46, 1.25) 0.29 0.82 (0.45, 1.50) 0.52
Physical activity
   No 1.00 (reference)
   Yes 0.51 (0.20, 1.27) 0.15 - -
DM 
   No 1.00 (reference) 1.00 (reference)
   Yes 0.77 (0.46, 1.27) 0.31 0.55 (0.29, 1.03) 0.06
HTN
   No 1.00 (reference)
   Yes - - 0.73 (0.43, 1.26) 0.27
ACS, acute coronary syndrome; aHR, adjusted hazard ratios; CI, confidence interval; SES, socioeconomic status; DM, diabetes mellitus; HTN, hypertension.  
1Adjusted for severity SES, employment status, physical activity, smoking status and DM.
2Adjusted for severity, sex, SES, employment status, smoking status, DM and HTN.
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mortality remained consistent when the analyses were strati-
fied based on HTN (Figure 1) and DM (Figure 2).  
DISCUSSION
The findings of this study suggest that ACS patients who are 
long-term users of areca nut may have a slightly higher risk of 
30-day mortality than non-users. This finding was not statisti-
cally significant when we controlled for other potential con-
founding factors such as smoking status, SES, the severity of 
disease, sex, and history of HT or DM. However, the severity of 
disease in ACS patients was found to be significantly related to 
the risk of 30-day re-hospitalization and mortality. Further-
more, we observed a significantly higher risk of 30-day re-hos-
pitalization among ACS patients who were areca nut users 
than among non-users. The doubled risk of re-hospitalization 
remained consistent when we accounted for the effects of 
age, sex, severity of disease, history of HTN, and other covari-
ates. These findings are not directly comparable with any pub-
lished findings, as to our knowledge no previous evidence has 
been reported regarding the relationship of areca nut chew-
ing to the prognosis of ACS patients. 
Some studies have reported that areca nut chewers had sig-
nificantly higher risks of cardiovascular and all-cause mortality 
Figure 1. Thirty-day mortality in acute coronary syndrome 
patients according to areca nut consumption stratified by 
DM and HTN. (A) Areca nut use and 30-day mortality risk. (B, C) 
Areca nut use and mortality stratified by the presence of DM. 
(D, E) Areca nut use and mortality stratified by the presence 
of HTN. DM, diabetes mellitus; HTN, hypertension.
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than non-users [18,19]. The increase in mortality may be due 
to a higher risk of developing coronary artery disease [25], 
atrial fibrillation [32], and other forms of CVD [22] in the first 
place among areca nut chewers than among non-chewers. 
Since areca nut chewers are at a higher risk of developing 
CVD’s, they may experience high rates of cardiovascular and 
all-cause mortality later on compared with non-chewers. Our 
study also highlights the role of areca nut chewing in the 
prognosis of ACS patients after the acute event. Our findings 
suggest a slight increase in mortality and a significant risk of 
re-hospitalization among chewers compared with non-chew-
ers. Several potential pathways can explain the observed dif-
ference in mortality and re-hospitalization between areca nut 
chewers and non-chewers.
Areca nut chewing is strongly linked with established CVD 
risk factors, including obesity [33], HTN [21], DM, and meta-
bolic syndrome. Furthermore, recent studies have also report-
ed that areca nut chewing increased systemic inflammation 
both in young [34] and middle-aged individuals [33]. Elevated 
inflammation may also explain the observation of subclinical 
atherosclerosis manifesting as increased carotid intima media 
thickness among areca nut chewers compared with non-
chewers [20]. In essence, the higher prevalence of CVD risk 
factors coupled with elevated systemic inflammation and un-
Figure 2. Re-hospitalization in acute coronary syndrome pa-
tients according to areca nut consumption stratified by DM 
and HTN. (A) Areca nut use and 30-day re-hospitalization risk. 
(B, C) Areca nut use and 30-day re-hospitalization stratified 
by the presence of DM. (D, E) Areca nut use and 30-day re-
hospitalization stratified by the presence of HTN. DM, diabe-
tes mellitus; HTN, hypertension.
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derlying atherosclerosis may explain the poor prognosis of 
areca nut chewers after ACS. However, the exact underlying 
biological mechanism that leads to repeated hospitalization 
and a slight increase in the risk of death needs further explora-
tion.        
To our knowledge, this is the first clinical study to examine 
the relationship between areca nut chewing and the short-
term prognosis of ACS patients. The prospective design and 
reasonably large sample with clinically diagnosed ACS make 
the findings of this study fairly robust. However, certain limita-
tions need to be highlighted. The sample of this study was re-
cruited from 2 public sector hospitals, and the majority of the 
patients were from low to lower-middle socioeconomic class-
es, which may limit the generalizability of this study. However, 
the areca nut chewing habit is also remarkably common in 
these SESs of the population [35], especially in comparison 
with the upper-middle and upper socioeconomic classes. 
Therefore, the sample recruited for this study may nonetheless 
be representative of middle-aged and elderly areca nut users 
in our population. Secondly, we relied on self-reporting of cig-
arette smoking and other health risk behaviors, which may 
have some potential to bias our results. For instance, the high-
er risk of re-hospitalization observed in this study may have 
been due to a differential distribution of health risk behaviors 
between areca nut chewers and non-chewers. Secondhand 
smoke is a particular concern in this regard, as higher expo-
sure to secondhand smoke among areca nut chewers may 
have led to increased re-hospitalization in this group. This is 
fairly plausible because many health risk behaviors are usually 
clustered together, and it may be reasonable to assume that 
areca nut chewers would have a higher exposure to second-
hand smoke than non-chewers. We do not have any evidence 
to support this possibility, but if it is true, the findings of this 
study may have been prone to confounding bias, which re-
mains the major limitation of this study. Nevertheless, we at-
tempted to control for the potential confounding effects of 
several covariates, and the overall findings of the study re-
mained consistent after multivariate adjustments. 
In conclusion, areca nut chewing significantly increased the 
risk of re-hospitalization among ACS patients; however, there 
is little evidence that it increased short-term mortality. Further 
evidence from large clinical studies is needed to validate our 
findings and to elucidate the biological mechanism underly-
ing these observations. 
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